These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22837211)

  • 21. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of respiratory syncytial virus (RSV) antigen in the lungs of guinea pigs 6 weeks after experimental infection and despite of the production of neutralizing antibodies.
    Streckert HJ; Philippou S; Riedel F
    Arch Virol; 1996; 141(3-4):401-10. PubMed ID: 8645083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.
    Chirkova T; Lin S; Oomens AGP; Gaston KA; Boyoglu-Barnum S; Meng J; Stobart CC; Cotton CU; Hartert TV; Moore ML; Ziady AG; Anderson LJ
    J Gen Virol; 2015 Sep; 96(9):2543-2556. PubMed ID: 26297201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
    Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.
    Spender LC; Hussell T; Openshaw PJ
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
    J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE
    J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
    Leemans A; De Schryver M; Van der Gucht W; Heykers A; Pintelon I; Hotard AL; Moore ML; Melero JA; McLellan JS; Graham BS; Broadbent L; Power UF; Caljon G; Cos P; Maes L; Delputte P
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virus infection.
    Gaddum RM; Cook RS; Wyld SG; López JA; Bustos R; Melero JA; Taylor G
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1239-48. PubMed ID: 8683212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.
    Plotnicky-Gilquin H; Cyblat-Chanal D; Aubry JP; Champion T; Beck A; Nguyen T; Bonnefoy JY; Corvaïa N
    J Virol; 2002 Oct; 76(20):10203-10. PubMed ID: 12239295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the role of respiratory syncytial virus surface glycoproteins F and G on viral stability and replication: implications for future vaccine design.
    DeFord DM; Nosek JM; Castiglia KR; Hasik EF; Franke ME; Nick BC; Abdelnour AM; Haas CE; Junod NA; Latsko KN; Moore ML; Berthrong ST; Rostad CA; Stobart CC
    J Gen Virol; 2019 Jul; 100(7):1112-1122. PubMed ID: 31184573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
    Zhu Q; Lu B; McTamney P; Palaszynski S; Diallo S; Ren K; Ulbrandt ND; Kallewaard N; Wang W; Fernandes F; Wong S; Svabek C; Moldt B; Esser MT; Jing H; Suzich JA
    J Infect Dis; 2018 Jul; 218(4):572-580. PubMed ID: 29617879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome.
    Xu J; Ding Y; Yang Y
    Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.
    Teng MN; Collins PL
    J Virol; 2002 Jun; 76(12):6164-71. PubMed ID: 12021350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
    Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG
    J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.